Skip to main content
. 2022 Feb 3;13(5):765–767. doi: 10.1111/jdi.13747

Figure 1.

Figure 1

Effect of canagliflozin on annual eGFR decline rate in diabetic kidney disease. Sub‐analysis of the Canagliflozin Cardiovascular Assessment Study (CANVAS) program showed a significant improvement in the annual decline rate of estimated glomerular filtration rate (eGFR) in the canagliflozin‐treated group compared with the placebo group, regardless of stage of albuminuria at entry (modified from Neuen et al. 12 ).